Thymalin
Polypeptide complex extracted from calf thymus containing short peptides (KE, EW, EDP) that regulate T-cell differentiation
- Class
- Thymic bioregulator
- Half-life
- ~7-14 days
- Route
- Intramuscular
- Cadence
- Cycled (on/off)
- Evidence
- Mixed / early human
Overview
Thymalin is a polypeptide complex extracted from the thymus glands of young calves — a mix of short peptides (mostly 2-8 amino acids) that mimic the signaling your thymus uses to train T-cells. It's been approved in Russia since the 1980s for immune restoration in elderly and immunocompromised people, and has decades of clinical use in former Soviet states. Outside that geography, almost nobody has heard of it.
The mechanism is epigenetic: the active peptides (KE, EW, EDP) bind directly to DNA and histone proteins in immune cells, switching on genes that drive T-cell differentiation and cytokine balance. It's not a receptor agonist in the classical sense — it works upstream, at the transcription level. The result is improved T-cell counts, better vaccine response, and reduced infection rates in older adults and people recovering from surgery or chemotherapy.
The catch: almost all the published evidence comes from Russian research groups, mostly open-label trials with small sample sizes. The most-cited longevity study (Khavinson 2003) reported a 4-year median survival advantage in elderly patients taking thymalin plus epithalamin vs placebo — but it was single-site, open-label, and has never been replicated in a Western trial. The peptide is not approved anywhere outside the former Soviet bloc, and the research-market version you'll find is unregulated and of unknown purity.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved by FDA, EMA, or MHRA. Approved in Russia since the 1980s, but no Western regulatory body has reviewed it. The peptide sold in research markets is unregulated — purity and actual peptide content vary wildly.
- Over 40 years of reported clinical use in Russia with minimal documented side effects in published trials. Most reports describe it as extremely well-tolerated. But the trial quality is mixed and almost all come from a single research group (Khavinson et al.).
- Contraindicated during menstruation, pregnancy, and in people with pituitary adenoma or acromegaly according to Russian prescribing information — presumably because of concerns about hormone-sensitive tissues.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Thymalin.
- Complete blood count (lymphocyte subsets, CD4/CD8 ratio if you can get it)
- Infection frequency — the clinical endpoint most trials tracked
- Vaccine response / antibody titers if you're using it around flu season
- Subjective recovery speed from illness or overtraining
- Inflammatory markers (CRP, IL-6) if you're tracking chronic inflammation
Frequently asked questions
What is Thymalin?
Polypeptide complex extracted from calf thymus containing short peptides (KE, EW, EDP) that regulate T-cell differentiation. Thymalin is a polypeptide complex extracted from the thymus glands of young calves — a mix of short peptides (mostly 2-8 amino acids) that mimic the signaling your thymus uses to train T-cells. It's been approved in Russia since the 1980s for immune restoration in elderly and immunocompromised people, and has decades of clinical use in former Soviet states. Outside that geography, almost nobody has heard of it.
How is Thymalin administered?
Intramuscular, typically cycled (on/off).
What is the half-life of Thymalin?
~7-14 days — Effects persist for weeks post-administration due to gene expression changes.
Is Thymalin approved for human use?
Thymalin is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Thymalin?
Evidence tier: Mixed / early human. <cite index="4-6,4-7">A 2021 Russian trial (n=36) tested thymalin as adjunct therapy in severe COVID-19 older patients; those who got thymalin showed faster lymphocyte recovery and lower C-reactive protein vs standard care alone</cite>.
What is commonly monitored when researching Thymalin?
Commonly tracked markers + signals: Complete blood count (lymphocyte subsets, CD4/CD8 ratio if you can get it), Infection frequency — the clinical endpoint most trials tracked, Vaccine response / antibody titers if you're using it around flu season, Subjective recovery speed from illness or overtraining, Inflammatory markers (CRP, IL-6) if you're tracking chronic inflammation.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.